Advertisement

Concurrent administration of anti-HER2 therapy and radiotherapy: Systematic review

      Abstract

      Background: Over the past few years, anti-HER2 targeted therapies have proven to be a key treatment in the management of human epidermal growth receptor 2 (HER2)-positive breast cancers, as well as gastrointestinal tract tumors and head and neck tumors. Anti-HER2 therapies administered alone or in combination with chemotherapy have been extensively studied, but only limited robust data are available concerning the safety and efficacy of anti-HER2 molecules in combination with radiotherapy. Methods: We searched on Medline, Embase and Cochrane databases the articles providing data on the concomitant association between the antiHER2 therapies used in clinical practice (trastuzumab, pertuzumab, lapatinib and T-DM1) with radiotherapy. The articles were selected according to their pre-clinical and clinical relevance. Results: The trastuzumab-irradiation combination is the most studied, with a focus on the cardiac toxicity. The combination of lapatinib-irradiation was particularly studied in the context of cerebral metastases of HER2-positive breast cancer. The data on pertuzumab and T-DM1 were poor and are mainly case reports. Conclusion: To date, reliable conclusions about the toxicity and/or efficacy of concomitant irradiation with anti-HER2 therapies are difficult to make due to the heterogeneity of the data in the literature and need to be confirmed on a larger scale and long term follow-up. Nevertheless, no serious adverse events are reported and the toxicity profile seems to be manageable.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Slamon D.J.
        • Clark G.M.
        • Wong S.G.
        • Levin W.J.
        • Ullrich A.
        • McGuire W.L.
        Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
        Science. 1987; 235: 177-182
        • Bang Y.-J.
        • Van Cutsem E.
        • Feyereislova A.
        • Chung H.C.
        • Shen L.
        • Sawaki A.
        • et al.
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet Lond Engl. 2010; 376: 687-697
        • Olayioye M.A.
        • Neve R.M.
        • Lane H.A.
        • Hynes N.E.
        The ErbB signaling network: receptor heterodimerization in development and cancer.
        EMBO J. 2000; 19: 3159-3167
        • Wolff A.C.
        • Hammond M.E.H.
        • Hicks D.G.
        • Dowsett M.
        • McShane L.M.
        • Allison K.H.
        • et al.
        Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
        J Clin Oncol. 2013; 31: 3997-4013
        • Penault-Llorca F.
        • Chenard M.-P.
        • Bouché O.
        • Emile J.-F.
        • Bibeau F.
        • Metges J.-P.
        • et al.
        HER2 and gastric cancer. Recommendations for clinical practice in 2011.
        Ann Pathol. 2011; 31: 78-87
        • Asanuma H.
        • Torigoe T.
        • Kamiguchi K.
        • Hirohashi Y.
        • Ohmura T.
        • Hirata K.
        • et al.
        Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
        Cancer Res. 2005; 65: 11018-11025
        • Molina M.A.
        • Codony-Servat J.
        • Albanell J.
        • Rojo F.
        • Arribas J.
        • Baselga J.
        Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
        Cancer Res. 2001; 61: 4744-4749
        • Barok M.
        • Isola J.
        • Palyi-Krekk Z.
        • Nagy P.
        • Juhász I.
        • Vereb G.
        • et al.
        Trastuzumab causes antibody-dependent cellular cytotoxicity- mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
        Mol Cancer Ther. 2007; 6: 2065-2072
        • Bruno R.
        • Washington C.B.
        • Lu J.-F.
        • Lieberman G.
        • Banken L.
        • Klein P.
        Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
        Cancer Chemother Pharmacol. 2005; 56: 361-369
        • Slamon D.J.
        • Leyland-Jones B.
        • Shak S.
        • Paton V.
        • Bajamonde A.
        • Fleming T.
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Smith I.
        • Procter M.
        • Gelber R.D.
        • Guillaume S.
        • Feyereislova A.
        • Dowsett M.
        • et al.
        2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
        Lancet Lond Engl. 2007; 369: 29-36
        • Segovia-Mendoza M.
        • González-González M.E.
        • Barrera D.
        • Díaz L.
        • García-Becerra R.
        Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.
        Am J Cancer Res. 2015; 5: 2531-2561
        • Konecny G.E.
        • Pegram M.D.
        • Venkatesan N.
        • Finn R.
        • Yang G.
        • Rahmeh M.
        • et al.
        Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
        Cancer Res. 2006; 66: 1630-1639
        • Geyer C.E.
        • Forster J.
        • Lindquist D.
        • Chan S.
        • Romieu C.G.
        • Pienkowski T.
        • et al.
        Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
        N Engl J Med. 2006; 355: 2733-2743
        • Blackwell K.L.
        • Burstein H.J.
        • Storniolo A.M.
        • Rugo H.S.
        • Sledge G.
        • Aktan G.
        • et al.
        Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
        J Clin Oncol. 2012; 30: 2585-2592
        • Bence A.K.
        • Anderson E.B.
        • Halepota M.A.
        • Doukas M.A.
        • DeSimone P.A.
        • Davis G.A.
        • et al.
        Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.
        Invest New Drugs. 2005; 23: 39-49
        • Adams C.W.
        • Allison D.E.
        • Flagella K.
        • Presta L.
        • Clarke J.
        • Dybdal N.
        • et al.
        Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.
        Cancer Immunol Immunother CII. 2006; 55: 717-727
        • Baselga J.
        • Cortés J.
        • Kim S.-B.
        • Im S.-A.
        • Hegg R.
        • Im Y.-H.
        • et al.
        Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
        N Engl J Med. 2012; 366: 109-119
        • Lewis Phillips G.D.
        • Li G.
        • Dugger D.L.
        • Crocker L.M.
        • Parsons K.L.
        • Mai E.
        • et al.
        Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
        Cancer Res. 2008; 68: 9280-9290
        • Verma S.
        • Miles D.
        • Gianni L.
        • Krop I.E.
        • Welslau M.
        • Baselga J.
        • et al.
        Blackwell K; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer.
        N Engl J Med. 2012; 367: 1783-1791
        • Krop I.E.
        • Kim S.-B.
        • González-Martín A.
        • LoRusso P.M.
        • Ferrero J.-M.
        • Smitt M.
        • et al.
        Wildiers H; TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 689-699
        • Girish S.
        • Gupta M.
        • Wang B.
        • Lu D.
        • Krop I.E.
        • Vogel C.L.
        • et al.
        Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
        Cancer Chemother Pharmacol. 2012; 69: 1229-1240
        • Liang K.
        • Lu Y.
        • Jin W.
        • Ang K.K.
        • Milas L.
        • Fan Z.
        Sensitization of breast cancer cells to radiation by trastuzumab.
        Mol Cancer Ther. 2003; 2: 1113-1120
        • Guo G.
        • Wang T.
        • Gao Q.
        • Tamae D.
        • Wong P.
        • Chen T.
        • et al.
        Expression of ErbB2 enhances radiation-induced NF- B activation.
        Oncogene. 2004; 23: 535-545
        • Pietras R.J.
        • Poen J.C.
        • Gallardo D.
        • Wongvipat P.N.
        • Lee H.J.
        • Slamon D.J.
        Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
        Cancer Res. 1999; 59: 1347-1355
        • Hou J.
        • Zhou Z.
        • Chen X.
        • Zhao R.
        • Yang Z.
        • Wei N.
        • et al.
        HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.
        Oncotarget. 2016; 7: 45186-45198
        • Papanikolaou V.
        • Iliopoulos D.
        • Dimou I.
        • Dubos S.
        • Kappas C.
        • Kitsiou-Tzeli S.
        • et al.
        Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells.
        J Cell Mol Med. 2011; 15: 1542-1550
        • Lazaro G.
        • Smith C.
        • Goddard L.
        • Jordan N.
        • McClelland R.
        • Barrett-Lee P.
        • et al.
        Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
        Endoc Relat Cancer. 2013; 20: 691-704
        • Kim J.S.
        • Kim H.A.
        • Seong M.K.
        • Seol H.
        • Oh J.S.
        • Kim E.K.
        • et al.
        STAT3-survivin signaling mediates a poor response to radiotherapy in HER2-positive breast cancers.
        Oncotarget. 2016; 7: 7055-7065
        • Zhang T.
        • Cui G.B.
        • Zhang J.
        • Zhang F.
        • Zhou Y.A.
        • Jiang T.
        • et al.
        Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation.
        Oncol Rep. 2010; 24: 1683-1689
        • Li H.F.
        • Kim J.S.
        • Waldman T.
        Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells.
        Radiat Oncol. 2009; 4: 43
        • Bussink J.
        • van der Kogel A.J.
        • Kaanders J.H.
        Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.
        Lancet Oncol. 2008; 9: 288-296
        • Sato S.
        • Kajiyama Y.
        • Sugano M.
        • Iwanuma Y.
        • Sonoue H.
        • Matsumoto T.
        • et al.
        Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
        Int J Radiat Oncol Biol Phys. 2005; 61: 203-211
        • Uno M.
        • Otsuki T.
        • Kurebayashi J.
        • Sakaguchi H.
        • Isozaki Y.
        • Ueki A.
        • et al.
        Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma.
        Int J Cancer. 2001; 94: 474-479
        • Bese N.S.
        • Umay C.
        • Serdengecti S.
        • Kepil N.
        • Sut N.
        • Altug T.
        • et al.
        The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study.
        Med Oncol Northwood Lond Engl. 2010; 27: 1415-1419
        • Yu T.
        • Cho B.J.
        • Choi E.F.
        • Park J.M.
        • Kim D.H.
        • Kim I.A.
        Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.
        Oncotarget. 2016; 7: 79089-79100
        • Sambade M.J.
        • Kimple R.J.
        • Camp J.T.
        • Peters E.
        • Livasy C.A.
        • Sartor C.I.
        • et al.
        Lapatinib in combinationison with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.
        Int J Radiat Oncol Biol Phys. 2010; 77: 575-581
        • Sambade M.J.
        • Camp J.T.
        • Kimple R.J.
        • Sartor C.I.
        • Shields J.M.
        Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition ok MEK.
        Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009; 93: 639-644
        • Adams S.R.
        • Yang H.S.
        • Savariar E.N.
        • Aguilera J.
        • Crisp J.L.
        • Jones K.A.
        • et al.
        Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.
        Nat Commun. 2016; 4: 13019
        • Mackey J.R.
        • Clemons M.
        • Côté M.A.
        • Delgado D.
        • Dent S.
        • Paterson A.
        • et al.
        Sawyer MB, and Verma. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group S.
        Curr Oncol. 2008; 15: 24-35
        • Darby S.C.
        • Ewertz M.
        • McGale P.
        • Bennet A.M.
        • Blom-Goldman U.
        • Brønnum D.
        • et al.
        Risk of ischemic heart disease in women after radiotherapy for breast cancer.
        N Engl J Med. 2013; 368: 987-998
        • Belkacémi Y.
        • Gligorov J.
        • Ozsahin M.
        • Marsiglia H.
        • De Lafontan B.
        • Laharie-Mineur H.
        • et al.
        Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.
        Ann Oncol. 2008; 19: 1110-1116
        • Shaffer R.
        • Tyldesley S.
        • Rolles M.
        • Chia S.
        • Mohamed I.
        Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
        Radiother Oncol J Eur Soc Ther Radiol Oncol. 2009; 90: 122-126
        • Cao L.
        • Cai G.
        • Chang C.
        • Yang Z.-Z.
        • Feng Y.
        • Yu X.-L.
        • et al.
        Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
        Oncotarget. 2016; 7: 1042-1054
        • Meattini I.
        • Cecchini S.
        • Muntoni C.
        • Scotti V.
        • De Luca Cardillo C
        • Mangoni M.
        • et al.
        Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.
        Med Oncol Northwood Lond Engl. 2014; 31: 891
        • Piccart-Gebhart M.J.
        • Procter M.
        • Leyland-Jones B.
        • Goldhirsch A.
        • Untch M.
        • Smith I.
        • et al.
        Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
        N Engl J Med. 2005; 53: 1659-1672
        • Joensuu H.
        • Kellokumpu-Lehtinen P.L.
        • Bono P.
        • Alanko T.
        • Kataja V.
        • Asola R.
        • et al.
        FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
        N Engl J Med. 2006; 354: 809-820
        • Romond E.H.
        • Perez E.A.
        • Bryant J.
        • Suman V.J.
        • Geyer C.E.
        • Davidson N.E.
        • et al.
        Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
        N Engl J Med. 2005; 353: 1673-1684
        • Halyard M.Y.
        • Pisansky T.M.
        • Dueck A.C.
        • Suman V.
        • Pierce L.
        • Solin L.
        • et al.
        Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
        J Clin Oncol. 2009; 27: 2638-2644
        • Jacob J.
        • Belin L.
        • Pierga J.Y.
        • Gobillion A.
        • Vincent-Salomon A.
        • Dendale R.
        • et al.
        Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study.
        Breast Cancer Res Treat. 2014; 148: 345-353
        • Caussa L.
        • Kirova Y.M.
        • Gault N.
        • Pierga J.-Y.
        • Savignoni A.
        • Campana F.
        The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
        Eur J Cancer Oxf Engl 1990. 2011; 47: 65-73
        • Procter M.
        • Suter T.M.
        • de Azambuja E.
        • Dafni U.
        • van Dooren V.
        • Muehlbauer S.
        • et al.
        Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
        J Clin Oncol. 2010; 28: 3422-3428
        • Joensuu H.
        • Bono P.
        • Kataja V.
        • Alanko T.
        • Kokko R.
        • Asola R.
        • et al.
        Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
        J Clin Oncol. 2009; 27: 5685-5692
        • Horton J.K.
        • Halle J.
        • Ferraro M.
        • Carey L.
        • Moore D.T.
        • Ollila D.
        • et al.
        Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
        Int J Radiat Oncol Biol Phys. 2010; 76: 998-1004
        • Huang E.
        • McNeese M.D.
        • Strom E.A.
        • Perkins G.H.
        • Katz A.
        • Hortobagyi G.N.
        • et al.
        Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1225-1233
        • Chargari C.
        • Idrissi H.R.
        • Pierga J.-Y.
        • Bollet M.A.
        • Diéras V.
        • Campana F.
        • et al.
        Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients.
        Int J Radiat Oncol Biol Phys. 2011; 81: 631-636
        • Stemmler H.-J.
        • Schmitt M.
        • Willems A.
        • Bernhard H.
        • Harbeck N.
        • et al.
        Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
        Anticancer Drugs. 2007; 18: 23-28
        • Bartsch R.
        • Rottenfusser A.
        • Wenzel C.
        • Dieckmann K.
        • Pluschnig U.
        • Altorjai G.
        • et al.
        Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
        J Neurooncol. 2007; 85: 311-317
        • Law A.B.
        • Evans T.
        • Hayward R.L.
        • Higgins G.S.
        • Murray K.L.
        • Summers D.
        • et al.
        Possible Radiation Sensitisation by Trastuzumab Leading to Radiation-Induced Myelitis.
        Breast Care Basel Switz. 2009; 4: 40-42
        • Safran H.
        • Dipetrillo T.
        • Akerman P.
        • Ng T.
        • Evans D.
        • Steinhoff M.
        • et al.
        Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
        Int J Radiat Oncol Biol Phys. 2007; 67: 405-409
        • Katz D.A.
        • Abrams R.A.
        • Sclamberg J.S.
        • Usha L.
        Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature.
        Pract Radiat Oncol. 2015; 5: 61-65
        • Williams M.D.
        • Roberts D.B.
        • Kies M.S.
        • Mao L.
        • Weber R.S.
        • El-Naggar A.K.
        Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
        Clin Cancer Res Off J Am Assoc Cancer Res. 2010; 16: 2266-2274
        • Gilbert M.R.
        • Sharma A.
        • Schmitt N.C.
        • Johnson J.T.
        • Ferris R.L.
        • Duvvuri U.
        • et al.
        A 20-year review of 75 cases of salivary duct carcinoma.
        JAMA Otolaryngol Head Neck Surg. 2016; 142: 489-495
        • Kimple R.J.
        • Horton J.K.
        • Livasy C.A.
        • Shields J.M.
        • Lawrence J.A.
        • Chiu W.M.
        • et al.
        Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.
        Oncologist. 2012; 17: 1496-1503
        • Bachelot T.
        • Romieu G.
        • Campone M.
        • Diéras V.
        • Cropet C.
        • Dalenc F.
        • et al.
        Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
        Lancet Oncol. 2013; 14: 64-71
        • Lin N.U.
        • Freedman R.A.
        • Ramakrishna N.
        • Younger J.
        • Storniolo A.M.
        • Bellon J.R.
        • et al.
        A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
        Breast Cancer Res Treat. 2013; 142: 405-414
        • Shibasaki M.
        • Tanabe A.
        • Toda T.
        • Sakata H.
        • Ijichi M.
        • Kusaka K.
        • et al.
        A case of effective whole-brain irradiation and lapatinib/capecitabine combination therapy for HER2-positive breast cancer with multiple brain metastases.
        Gan To Kagaku Ryoho. 2015; 42: 755-757
        • Yomo S.
        • Hayashi M.
        • Cho N.
        Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
        J Neurooncol. 2013; 112: 199-207
        • Harrington K.
        • Berrier A.
        • Robinson M.
        • Remenar E.
        • Housset M.
        • de Mendoza F.H.
        • et al.
        Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
        Eur J Cancer Oxf Engl 1990. 2013; 49: 1609-1618
        • Ajgal Z.
        • de Percin S.
        • Diéras V.
        • Pierga J.Y.
        • Campana F.
        • Fourquet A.
        • et al.
        Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
        Cancer Radiother. 2017; S1278–3218: 30044-30046
        • Krop I.E.
        • Suter T.M.
        • Dang C.T.
        • Dirix L.
        • Romieu G.
        • Zamagni C.
        • et al.
        Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
        J Clin Oncol. 2015; 33: 1136-1142
        • Borges G.S.
        • Rovere R.K.
        • Dias S.M.K.
        • Chong F.H.
        • Morais M.D.S.
        Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature.
        Ecancermedicalscience. 2015; 9: 586
        • Carlson J.A.
        • Nooruddin Z.
        • Rusthoven C.
        • Elias A.
        • Borges V.F.
        • Diamond J.R.
        • et al.
        Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.
        Neuro-Oncol. 2014; 16: 1006-1009
        • Geraud A.
        • Xu H.P.
        • Beuzeboc P.
        • Kirova Y.M.
        Preliminary experience of the concurrent use of radiosurgery and TDM1 for brain metastases in HER2 positive metastatic breast cancer.
        J Neurooncol. 2017; 131: 69-72
        • Mitsuya K.
        • Watanabe J.
        • Nakasu Y.
        • Hayashi N.
        • Harada H.
        • Ito I.
        Expansive hematoma in delayed cerebral radiation necrosis in patients treated with TDM1 a report of two cases.
        BMC Cancer. 2016; 4: 391